Novartis Ag (NVS) Receivables - Other (2017 - 2025)

Novartis Ag (NVS) has 9 years of Receivables - Other data on file, last reported at $1.1 billion in Q4 2025.

• Quarterly Receivables - Other rose 4.01% year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 billion (up 4.01% YoY) and the FY2025 annual result came in at $1.1 billion, up 4.01% from the prior year.
• Receivables - Other rose to $1.1 billion in Q4 2025 per NVS's latest filing, from $1.1 billion in the prior quarter.
• The five-year high for Receivables - Other was $1.3 billion in Q4 2023, with the low at $793.0 million in Q4 2021.
• Average Receivables - Other over 5 years is $1.0 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Receivables - Other retreated 17.65% in 2021 and jumped 30.69% in 2023.
• Novartis Ag's Receivables - Other stood at $793.0 million in 2021, then advanced by 20.81% to $958.0 million in 2022, then jumped by 30.69% to $1.3 billion in 2023, then retreated by 12.38% to $1.1 billion in 2024, then grew by 4.01% to $1.1 billion in 2025.
• Business Quant data shows NVS's Receivables - Other at $1.1 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.3 billion in Q4 2023.